Opexa's share price tumbles as lead MS drug fails
This article was originally published in Scrip
Executive Summary
Shares in the US biotech company Opexa Therapeutics lost 94% of their value after a Phase IIb study of its lead product Tovaxin failed. The firm's share price on Nasdaq closed at $0.22 on September 19th after the top-line data were released at the World Congress on Treatment and Research in Multiple Sclerosis in Montreal, Canada.